Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/199885
Title: Molecular characterization of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
Author: Pinyol, Roser
Torrecilla, Sara
Wang, Huan
Montironi, Carla
Piqué Gili, Marta
Torres Martín, Miguel
Wei-Qiang, Leow
Willoughby, Catherine E.
Ramadori, Pierluigi
Andreu Oller, Carmen
Taik, Patricia
Lee, Youngmin A.
Moeini, Agrin
Peix, Judit
Faure-Dupuy, Suzanne
Riedl, Tobias
Schuehle, Svenja
Oliveira, Claudia P.
Alves, Venancio A.
Boffetta, Paolo
Lachenmayer, Anja
Roessler, Sthephanie
Minguez, Beatriz
Schirmacher, Peter
Dufour, Jean François
Thung, Swan N.
Reeves, Helen L.
Carrilho, Flair J.
Chang, Charissa
Uzilov, Andrew V.
Heikenwalder, Mathias
Sanyal, Arun
Friedman, Scott L.
Sia, Daniela
Llovet i Bayer, Josep Maria
Keywords: Models animals en la investigació
Càncer de fetge
Síndrome metabòlica
Models moleculars
Mutació (Biologia)
Obesitat
Animal models in research
Liver cancer
Metabolic syndrome
Molecular models
Mutation (Biology)
Obesity
Issue Date: 13-May-2021
Publisher: Elsevier
Abstract: Background and aims: Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) is increasing globally, but its molecular features are not well defined. We aimed to identify unique molecular traits characterising NASH-HCC compared to other HCC aetiologies. Methods: We collected 80 NASH-HCC and 125 NASH samples from 5 institutions. Expression array (n = 53 NASH-HCC; n = 74 NASH) and whole exome sequencing (n = 52 NASH-HCC) data were compared to HCCs of other aetiologies (n = 184). Three NASH-HCC mouse models were analysed by RNA-seq/expression-array (n = 20). Activin A receptor type 2A (ACVR2A) was silenced in HCC cells and proliferation assessed by colorimetric and colony formation assays. Results: Mutational profiling of NASH-HCC tumours revealed TERT promoter (56%), CTNNB1 (28%), TP53 (18%) and ACVR2A (10%) as the most frequently mutated genes. ACVR2A mutation rates were higher in NASH-HCC than in other HCC aetiologies (10% vs. 3%, p <0.05). In vitro, ACVR2A silencing prompted a significant increase in cell proliferation in HCC cells. We identified a novel mutational signature (MutSig-NASH-HCC) significantly associated with NASH-HCC (16% vs. 2% in viral/alcohol-HCC, p = 0.03). Tumour mutational burden was higher in non-cirrhotic than in cirrhotic NASH-HCCs (1.45 vs. 0.94 mutations/megabase; p <0.0017). Compared to other aetiologies of HCC, NASH-HCCs were enriched in bile and fatty acid signalling, oxidative stress and inflammation, and presented a higher fraction of Wnt/TGF-β proliferation subclass tumours (42% vs. 26%, p = 0.01) and a lower prevalence of the CTNNB1 subclass. Compared to other aetiologies, NASH-HCC showed a significantly higher prevalence of an immunosuppressive cancer field. In 3 murine models of NASH-HCC, key features of human NASH-HCC were preserved. Conclusions: NASH-HCCs display unique molecular features including higher rates of ACVR2A mutations and the presence of a newly identified mutational signature. Lay summary: The prevalence of hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH) is increasing globally, but its molecular traits are not well characterised. In this study, we uncovered higher rates of ACVR2A mutations (10%) - a potential tumour suppressor - and the presence of a novel mutational signature that characterises NASH-related HCC.
Note: Versió postprint del document publicat a: https://doi.org/10.1016/j.jhep.2021.04.049
It is part of: Journal of Hepatology, 2021, vol. 75, num. 4, p. 865-878
URI: http://hdl.handle.net/2445/199885
Related resource: https://doi.org/10.1016/j.jhep.2021.04.049
ISSN: 0168-8278
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
718036.pdf664.46 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons